Loading patent…
AssigneeThe General Hospital Corporation
InventorHyungsoon Im
Estimating the term…
The present disclosure relates to devices (e.g., nano-plasmonic chips carrying arrays of nanowells) and methods for the detection of cancer (e.g., CCA). Specifically, extracellular vesicles (EVs) can be captured in the nanowells of the nano-plasmonic chips and are then subject to multi-channel imaging that detects the presence and/or level of biomarkers associated with cancers such as CCA. Accordingly, in one aspect, provided herein are methods of detecting extracellular vesicles (EVs) from cholangiocarcinoma (CCA) cells in a sample, the method comprising: obtaining a sample, e.g., from a subject; isolating EVs from the sample; capturing EVs isolated from the sample on a nano-plasmonic chip bearing an array of nanostructures coated with a layer of gold; and detecting the presence and/or levels of one or more of MUC 1, EGER, and EpCAM, wherein a higher expression level of one or more of MUC1, EGFR, and EpCAM compared to a corresponding reference level indicates that the sample includes EVs from CCA cells.
A method of detecting extracellular vesicles (EVs) from cholangiocarcinoma (CCA) cells in a sample, the method comprising:
(canceled)
The method of claim 22, wherein the binding ligand is an antibody comprising a fluorophore-conjugated fluorescence primary antibody or an unconjugated primary antibody, with fluorophore-conjugated secondary antibodies labeling the primary antibody.
(canceled)
14-19. (canceled)
A nanowell nano-plasmonic chip for detecting target extracellular vesicles (EVs) in a sample, comprising
A method of producing a nanowell nano-plasmonic chip, the method comprising
(canceled)
30-43. (canceled)
Dependencies are inferred from the claim text.